Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Jianda Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C. Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao, Heinz Zwierzina, Lisa H. Butterfield, Bernard A. Fox

Research output: Contribution to journalReview article

94 Citations (Scopus)

Abstract

The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.

Original languageEnglish
Article number3
JournalJournal for ImmunoTherapy of Cancer
Volume4
Issue number1
DOIs
Publication statusPublished - 19 Jan 2016
Externally publishedYes

Fingerprint

Tumor Biomarkers
Immunotherapy
Technology
Biomarkers
Neoplasms
Advisory Committees
Immune System
Therapeutics
Industry
Research

Keywords

  • Bioinformatics
  • Biomarkers
  • Cancer immunotherapy
  • Immune checkpoint blockade
  • Immune monitoring
  • Task Force
  • Technology

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Immunology

Cite this

Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., ... Fox, B. A. (2016). Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 4(1), [3]. https://doi.org/10.1186/s40425-016-0107-3

Novel technologies and emerging biomarkers for personalized cancer immunotherapy. / Yuan, Jianda; Hegde, Priti S.; Clynes, Raphael; Foukas, Periklis G.; Harari, Alexandre; Kleen, Thomas O.; Kvistborg, Pia; Maccalli, Cristina; Maecker, Holden T.; Page, David B.; Robins, Harlan; Song, Wenru; Stack, Edward C.; Wang, Ena; Whiteside, Theresa L.; Zhao, Yingdong; Zwierzina, Heinz; Butterfield, Lisa H.; Fox, Bernard A.

In: Journal for ImmunoTherapy of Cancer, Vol. 4, No. 1, 3, 19.01.2016.

Research output: Contribution to journalReview article

Yuan, J, Hegde, PS, Clynes, R, Foukas, PG, Harari, A, Kleen, TO, Kvistborg, P, Maccalli, C, Maecker, HT, Page, DB, Robins, H, Song, W, Stack, EC, Wang, E, Whiteside, TL, Zhao, Y, Zwierzina, H, Butterfield, LH & Fox, BA 2016, 'Novel technologies and emerging biomarkers for personalized cancer immunotherapy', Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 3. https://doi.org/10.1186/s40425-016-0107-3
Yuan, Jianda ; Hegde, Priti S. ; Clynes, Raphael ; Foukas, Periklis G. ; Harari, Alexandre ; Kleen, Thomas O. ; Kvistborg, Pia ; Maccalli, Cristina ; Maecker, Holden T. ; Page, David B. ; Robins, Harlan ; Song, Wenru ; Stack, Edward C. ; Wang, Ena ; Whiteside, Theresa L. ; Zhao, Yingdong ; Zwierzina, Heinz ; Butterfield, Lisa H. ; Fox, Bernard A. / Novel technologies and emerging biomarkers for personalized cancer immunotherapy. In: Journal for ImmunoTherapy of Cancer. 2016 ; Vol. 4, No. 1.
@article{4604a65f4bd140e1a689f1384b0b52ca,
title = "Novel technologies and emerging biomarkers for personalized cancer immunotherapy",
abstract = "The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.",
keywords = "Bioinformatics, Biomarkers, Cancer immunotherapy, Immune checkpoint blockade, Immune monitoring, Task Force, Technology",
author = "Jianda Yuan and Hegde, {Priti S.} and Raphael Clynes and Foukas, {Periklis G.} and Alexandre Harari and Kleen, {Thomas O.} and Pia Kvistborg and Cristina Maccalli and Maecker, {Holden T.} and Page, {David B.} and Harlan Robins and Wenru Song and Stack, {Edward C.} and Ena Wang and Whiteside, {Theresa L.} and Yingdong Zhao and Heinz Zwierzina and Butterfield, {Lisa H.} and Fox, {Bernard A.}",
year = "2016",
month = "1",
day = "19",
doi = "10.1186/s40425-016-0107-3",
language = "English",
volume = "4",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Novel technologies and emerging biomarkers for personalized cancer immunotherapy

AU - Yuan, Jianda

AU - Hegde, Priti S.

AU - Clynes, Raphael

AU - Foukas, Periklis G.

AU - Harari, Alexandre

AU - Kleen, Thomas O.

AU - Kvistborg, Pia

AU - Maccalli, Cristina

AU - Maecker, Holden T.

AU - Page, David B.

AU - Robins, Harlan

AU - Song, Wenru

AU - Stack, Edward C.

AU - Wang, Ena

AU - Whiteside, Theresa L.

AU - Zhao, Yingdong

AU - Zwierzina, Heinz

AU - Butterfield, Lisa H.

AU - Fox, Bernard A.

PY - 2016/1/19

Y1 - 2016/1/19

N2 - The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.

AB - The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.

KW - Bioinformatics

KW - Biomarkers

KW - Cancer immunotherapy

KW - Immune checkpoint blockade

KW - Immune monitoring

KW - Task Force

KW - Technology

UR - http://www.scopus.com/inward/record.url?scp=84998865518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998865518&partnerID=8YFLogxK

U2 - 10.1186/s40425-016-0107-3

DO - 10.1186/s40425-016-0107-3

M3 - Review article

VL - 4

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 3

ER -